UC & University of Cincinnati to host Phase 3 COVID-19 vaccine trial

Date: 2020-06-19   Author: Saipriya Iyer  Category: #news

UC & University of Cincinnati to host Phase 3 COVID-19 vaccine trial

UC Health and the University of Cincinnati are reportedly planning to initiate a Phase 3 clinical study of the COVID-19 vaccine, mRNA-1273. This front-runner vaccine has been developed by the collaborators at Moderna and the NIAID (National Institute of Allergy & Infectious Diseases).

UC has reportedly cited that the previous trial showed the vaccine eliciting immune response like that of the COVID-19 recovered patients.

The 3rd phase of the clinical trial will offer data about the efficacy of the mRNA-1273 vaccine. UC is one of the sites approved across the United States to conduct the COVID-19 study, which plans to enroll over 30,000 people in the study nationwide. Additionally, UC seeks to enroll 500 patients locally. The vaccine reportedly has an 80 to 90% chance of obtaining the U.S. FDA approval.

The eligible candidates are of 18 years and older, with no track record of contracting the virus, but are at the risk of getting infected. The candidates will obtain this vaccine or a placebo and are required to maintain a daily record of the symptoms. They also must participate in Telehealth as well as clinical visits with UC Health’s clinicians for 2 years. The enrollment of the participants is expected to start in July.

Carl Fichtenbaum, professor of Internal Medicine Department at the University of Cincinnati College of Medicine, is the co-investigator of the trial & will serve as the medical director. Mr. Fichtenbaum has reportedly stated that the clinicians are excited to conduct the leading-edge research to contribute to the fight against the ongoing COVID-19 pandemic.

He further added that the Moderna vaccine technology uses a genetic code to generate proteins like those in infected patients to enable a rapid response of the body. Unlike conventional vaccines, mRNA vaccines help body cells communicate and direct the cells to produce proteins. This also enables the immune system to get stimulated & efficiently respond, without directly exposure to the virus.

Source credit:

https://www.fox19.com/2020/06/17/uc-health-hosting-phase-clinical-trial-front-runner-covid-vaccine-candidate/



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Antenatal Screening Market Share, By Product Analysis, Application, End-Use, Regional Outlook, Competitive Strategies & Forecast up to 2028

Author: Ashwin Naphade

Global Antenatal Screening Market, 2022-2028 Research Report provides crucial statistics on the market status of the Global Antenatal Screening manufacturers and is a respected source of guidance and direction for companies and individuals interes...


Pediatric Vitrectomy Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2028

Author: Ashwin Naphade

Global Pediatric Vitrectomy market report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The Pediatric Vitrectomy market repor...


Legionnaire Disease Testing Market Comprehensive Analysis, Share, Growth Forecast from 2022 to 2028c

Author: Ashwin Naphade

This report studies the Global Legionnaire Disease Testing market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, ...